Lung-MAP Infographics Illustrate How the Trial is Helping Patients
Cure Today – Basket Cases: Changing the Way Cancer Is Treated
Inside Health Policy – Woodcock Says Drug Development Paradigm Needs To Change, But Not At FDA
Lung-MAP Precision Medicine Trial Makes Exciting Changes, With New Science and Treatment Options for Patients
For Immediate Release Feb. 29, 2016 Please Contact: Ryan Hohman, JD, Managing Director, Policy and Public Affairs, Friends of Cancer Research: 202.944.6708 – rhohman@focr.org Wendy Lawton, Communications and Public Relations Manager, SWOG: 503.348.8675 –lawtonw@ohsu.edu Lung-MAP Precision Medicine Trial Makes Exciting Changes, With New Science and Treatment Options for Patients Lung-MAP, the most collaborative and comprehensive lung cancer clinical…
OncLive – New Trial Designs Hope to Enhance Biomarker Discovery
UAB News – Two major national clinical trials available for lung cancer patients at UAB
Cancer Letter – How the Lung-MAP Clinical Trial is Responding to Rapidly Changing Science
Statement from Lung-MAP Clinical Trial Leadership Regarding FDA Approval of Nivolumab
For Immediate Release Media Contact: Ryan Hohman, JD, Managing Director, Policy and Public Affairs, Friends of Cancer Research: 202.944.6708 – rhohman@focr.org or Frank DeSanto, Communications Manager, SWOG Cancer Research: 503.348.1710 – desanto@oshu.edu Statement from Lung-MAP Clinical Trial Leadership Regarding FDA Approval of Nivolumab On March 4, 2015, the U.S. Food and Drug Administration (FDA) announced…
Innovative Lung-MAP Lung Cancer Trial Open and Enrolling Patients at over 400 Sites in 39 States
For Immediate Release Please Contact: Ryan Hohman, JD, Managing Director, Policy and Public Affairs, Friends of Cancer Research: 202.944.6708 – rhohman@focr.org or Frank DeSanto, Communications Manager, SWOG Cancer Research: 503.348.1710 – desanto@oshu.edu Innovative Lung-MAP Lung Cancer Trial Open and Enrolling Patients at over 400 Sites in 39 States Trial will Close One of Five Trial…